|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: UTP14A |
Gene summary for UTP14A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | UTP14A | Gene ID | 10813 |
| Gene name | UTP14A small subunit processome component | |
| Gene Alias | NYCO16 | |
| Cytomap | Xq26.1 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q9BVJ6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10813 | UTP14A | P130T-E | Human | Esophagus | ESCC | 3.37e-37 | 6.63e-01 | 0.1676 |
| 10813 | UTP14A | HCC1_Meng | Human | Liver | HCC | 1.08e-42 | 1.00e-01 | 0.0246 |
| 10813 | UTP14A | HCC2_Meng | Human | Liver | HCC | 3.76e-11 | 9.70e-02 | 0.0107 |
| 10813 | UTP14A | cirrhotic2 | Human | Liver | Cirrhotic | 1.05e-03 | 6.12e-02 | 0.0201 |
| 10813 | UTP14A | HCC2 | Human | Liver | HCC | 2.66e-03 | 2.77e+00 | 0.5341 |
| 10813 | UTP14A | S014 | Human | Liver | HCC | 9.74e-15 | 4.63e-01 | 0.2254 |
| 10813 | UTP14A | S015 | Human | Liver | HCC | 3.34e-08 | 3.99e-01 | 0.2375 |
| 10813 | UTP14A | S016 | Human | Liver | HCC | 2.28e-21 | 5.32e-01 | 0.2243 |
| 10813 | UTP14A | S027 | Human | Liver | HCC | 5.69e-07 | 6.05e-01 | 0.2446 |
| 10813 | UTP14A | S028 | Human | Liver | HCC | 6.31e-11 | 5.50e-01 | 0.2503 |
| 10813 | UTP14A | S029 | Human | Liver | HCC | 8.71e-15 | 6.98e-01 | 0.2581 |
| 10813 | UTP14A | C04 | Human | Oral cavity | OSCC | 1.76e-07 | 6.04e-01 | 0.2633 |
| 10813 | UTP14A | C21 | Human | Oral cavity | OSCC | 2.05e-22 | 6.58e-01 | 0.2678 |
| 10813 | UTP14A | C30 | Human | Oral cavity | OSCC | 8.33e-23 | 9.59e-01 | 0.3055 |
| 10813 | UTP14A | C38 | Human | Oral cavity | OSCC | 2.20e-03 | 3.09e-01 | 0.172 |
| 10813 | UTP14A | C43 | Human | Oral cavity | OSCC | 2.59e-33 | 5.64e-01 | 0.1704 |
| 10813 | UTP14A | C46 | Human | Oral cavity | OSCC | 8.76e-10 | 2.44e-01 | 0.1673 |
| 10813 | UTP14A | C51 | Human | Oral cavity | OSCC | 1.47e-08 | 4.64e-01 | 0.2674 |
| 10813 | UTP14A | C06 | Human | Oral cavity | OSCC | 3.38e-02 | 7.08e-01 | 0.2699 |
| 10813 | UTP14A | C07 | Human | Oral cavity | OSCC | 5.98e-04 | 4.81e-01 | 0.2491 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0022613111 | Esophagus | ESCC | ribonucleoprotein complex biogenesis | 365/8552 | 463/18723 | 1.74e-49 | 1.11e-45 | 365 |
| GO:0042254111 | Esophagus | ESCC | ribosome biogenesis | 252/8552 | 299/18723 | 3.27e-44 | 1.04e-40 | 252 |
| GO:003447015 | Esophagus | ESCC | ncRNA processing | 300/8552 | 395/18723 | 3.09e-35 | 3.26e-32 | 300 |
| GO:0016072110 | Esophagus | ESCC | rRNA metabolic process | 197/8552 | 236/18723 | 1.31e-33 | 1.18e-30 | 197 |
| GO:0006364110 | Esophagus | ESCC | rRNA processing | 189/8552 | 225/18723 | 4.88e-33 | 3.87e-30 | 189 |
| GO:003466012 | Esophagus | ESCC | ncRNA metabolic process | 346/8552 | 485/18723 | 4.35e-31 | 2.51e-28 | 346 |
| GO:002261312 | Liver | Cirrhotic | ribonucleoprotein complex biogenesis | 231/4634 | 463/18723 | 3.28e-32 | 6.86e-29 | 231 |
| GO:004225412 | Liver | Cirrhotic | ribosome biogenesis | 154/4634 | 299/18723 | 1.18e-23 | 6.72e-21 | 154 |
| GO:000636412 | Liver | Cirrhotic | rRNA processing | 115/4634 | 225/18723 | 1.12e-17 | 1.64e-15 | 115 |
| GO:00160724 | Liver | Cirrhotic | rRNA metabolic process | 119/4634 | 236/18723 | 1.19e-17 | 1.70e-15 | 119 |
| GO:00344701 | Liver | Cirrhotic | ncRNA processing | 158/4634 | 395/18723 | 1.09e-11 | 6.96e-10 | 158 |
| GO:00346603 | Liver | Cirrhotic | ncRNA metabolic process | 173/4634 | 485/18723 | 3.64e-08 | 1.21e-06 | 173 |
| GO:002261322 | Liver | HCC | ribonucleoprotein complex biogenesis | 355/7958 | 463/18723 | 7.76e-52 | 4.92e-48 | 355 |
| GO:004225422 | Liver | HCC | ribosome biogenesis | 246/7958 | 299/18723 | 4.99e-46 | 1.58e-42 | 246 |
| GO:00344702 | Liver | HCC | ncRNA processing | 293/7958 | 395/18723 | 4.26e-38 | 6.76e-35 | 293 |
| GO:001607212 | Liver | HCC | rRNA metabolic process | 193/7958 | 236/18723 | 1.26e-35 | 1.14e-32 | 193 |
| GO:000636421 | Liver | HCC | rRNA processing | 185/7958 | 225/18723 | 8.14e-35 | 6.45e-32 | 185 |
| GO:00346601 | Liver | HCC | ncRNA metabolic process | 332/7958 | 485/18723 | 1.48e-31 | 7.80e-29 | 332 |
| GO:002261320 | Oral cavity | OSCC | ribonucleoprotein complex biogenesis | 333/7305 | 463/18723 | 8.28e-48 | 5.24e-44 | 333 |
| GO:004225420 | Oral cavity | OSCC | ribosome biogenesis | 230/7305 | 299/18723 | 3.22e-41 | 6.80e-38 | 230 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| UTP14A | SNV | Missense_Mutation | c.1178C>T | p.Pro393Leu | p.P393L | Q9BVJ6 | protein_coding | tolerated(0.13) | benign(0.034) | TCGA-A2-A04N-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD | |
| UTP14A | SNV | Missense_Mutation | rs754696456 | c.1874N>C | p.Asp625Ala | p.D625A | Q9BVJ6 | protein_coding | deleterious(0) | probably_damaging(0.963) | TCGA-A2-A0CS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD |
| UTP14A | SNV | Missense_Mutation | c.1544N>C | p.Glu515Ala | p.E515A | Q9BVJ6 | protein_coding | deleterious(0.01) | benign(0.32) | TCGA-A8-A081-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| UTP14A | SNV | Missense_Mutation | c.1948N>G | p.Leu650Val | p.L650V | Q9BVJ6 | protein_coding | deleterious(0.01) | possibly_damaging(0.557) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| UTP14A | SNV | Missense_Mutation | c.1516N>A | p.Glu506Lys | p.E506K | Q9BVJ6 | protein_coding | tolerated(0.22) | benign(0.09) | TCGA-B6-A1KF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| UTP14A | SNV | Missense_Mutation | novel | c.224N>G | p.Asn75Ser | p.N75S | Q9BVJ6 | protein_coding | tolerated(0.57) | benign(0.005) | TCGA-B6-A400-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| UTP14A | SNV | Missense_Mutation | c.2258N>T | p.Asn753Ile | p.N753I | Q9BVJ6 | protein_coding | tolerated_low_confidence(0.13) | benign(0.01) | TCGA-E2-A14V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| UTP14A | SNV | Missense_Mutation | novel | c.122N>C | p.Arg41Thr | p.R41T | Q9BVJ6 | protein_coding | deleterious(0) | probably_damaging(0.925) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| UTP14A | SNV | Missense_Mutation | c.1600G>A | p.Glu534Lys | p.E534K | Q9BVJ6 | protein_coding | tolerated(0.6) | benign(0.01) | TCGA-HM-A3JK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| UTP14A | SNV | Missense_Mutation | novel | c.1246N>C | p.Glu416Gln | p.E416Q | Q9BVJ6 | protein_coding | deleterious(0.01) | possibly_damaging(0.756) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |